Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
50 hedge funds and large institutions have $1.05B invested in Centessa Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
52.74% more ownership
Funds ownership: 0% → 52.74% (+53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$421M |
| 2 |
Janus Henderson Group
London,
|
+$134M |
| 3 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
+$92.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.3M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$36.1M |
Top Sellers
CNTA Hedge Fund Activity: Q2 2021 in Review
50 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2021, worth a combined $1.05B.
Buyers outnumbered sellers: 50 funds opened new CNTA positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Medicxi Ventures Management, opening a new position worth an estimated $421M.
- 50 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $1.05B of Centessa Pharmaceuticals stock for Q2 2021.
- 50 funds opened new Centessa Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +50 holders.
- The largest Centessa Pharmaceuticals buyer in Q2 2021 was Medicxi Ventures Management, an estimated $421M added.
Based on aggregated 13F filings for Q2 2021.